The Trump administration this month scrapped a Biden-era proposal that would have required state Medicaid programs and ...

The Trump administration this month scrapped a Biden-era proposal that would have required state Medicaid programs and ...

President Donald Trump is under pressure to decide how widely available anti-obesity drugs should be and whether Medicare should cover them.

Weight-loss medications such as Ozempic, Wegovy, and Mounjaro have attracted widespread attention, making headlines across ...

Click in for more news from The Hill{beacon} Health Care Health Care   The Big Story Novo Nordisk partners with telehealth ...

Donald Trump, at 78, is aggressively pursuing his second term, marked by significant policy changes and a noticeable physical ...

UB researcher Nicole Albanese talks about recent developments, including the end of the shortage of weight-loss drugs and the ...

Pa., said Mounjaro changed his life with 'significant' health benefits. He's calling for widespread access to GLP-1 ...

Wegovy and Zepbound, the two leading weight-loss drugs, together sold less than $5 billion in 2023, according to ...

The decision counters a proposal by the Biden Administration to reimburse beneficiaries for the weight-loss medications.

Due to current legislation regarding weight loss drugs, Medicare Part D or Part C plans with drug coverage may only cover Zepbound for treating obstructive sleep apnea (OSA). However, the Centers ...

Three years since COVID-19 abated, UnitedHealth Group, CVS Health and other insurers are still feeling the hangover, ...